Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self)~* Participants unsatisfied with their previous treatment~* Previously or currently on oral atypical antipsychotics~Exclusion Criteria:~* Serious unstable medical condition, including recent and present clinically relevant laboratory abnormalities~* History or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body)~* History of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)~* Pregnant or breast-feeding female~* Participation in an investigational drug trial within 30 days prior to selection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paliperidone Extended Release (ER) (Type: EXPERIMENTAL): Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).